QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,036 signal articles · 527 in last 24h · 103,484 total before filter · latest 31m ago
527last 24h
2509last 7d
482● bullish (7d)
257● bearish (7d)
197publishers
AllMacro242Earnings1479M&A140Regulatory16Product4Analyst29
✕ clear all filtersticker: GILDsentiment: bearishSentiment:bullishneutralbearishshow all (incl. clickbait)
Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut?
Barrons.com89d agobearish
Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut?

Gilead Sciences beat analysts’ earnings and revenue expectations in its latest quarter. Gilead logged adjusted earnings of $2.03 a share, ahead of the $1.91 consensus among analysts polled by FactSet. Gilead’s top-line growth rested heavily on Biktarvy, its blockbuster HIV treatment, which accounted for nearly half of total revenue as sales rose 8% to $3.4 billion.

GILD